ZANTAC Injection Gets FDA Blessing Despite Chemical Concerns
Published Date: 12/12/2025
Notice
Summary
The FDA has decided that ZANTAC injection (25 mg/mL) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet safety rules, especially about tiny impurities. Patients and drug makers can breathe easy knowing ZANTAC injection stays available under strict quality checks.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Generics Can Still Be Approved
The FDA says it will continue to approve abbreviated new drug applications (ANDAs) that refer to ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, as long as the applicants meet all legal and regulatory requirements. That includes satisfying any applicable acceptable intake limit for nitrosamine impurities before approval is granted.
Existing ANDA Approvals Protected
FDA will not begin procedures to withdraw approval of any approved ANDAs that refer to ZANTAC (ranitidine HCl) injection, EQ 25 mg base/mL. The listed product remains in the Orange Book's Discontinued Drug Product List, but existing ANDA approvals that reference it will not be subject to withdrawal procedures based on safety or effectiveness.
Patient Access to ZANTAC Injection
If you are a patient who needs ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, the FDA determined the product was not withdrawn for safety or effectiveness reasons so long as it can be made to meet nitrosamine impurity limits. That means the drug can remain available through generic approvals if manufacturers meet those safety limits.
Nitrosamine Limits Required for Approval
FDA's determination is conditional: the drug must be manufactured or formulated in a way that satisfies any applicable acceptable intake limit for nitrosamine impurities before ANDAs can be approved. Applicants must meet those nitrosamine intake limits and other regulatory requirements for approval to proceed.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2025-22675 — National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a virtual meeting on January 27, 2026, to discuss research updates and review grant applications. Anyone interested can watch the open session online, but the grant review part is private to protect sensitive info. This meeting affects researchers and organizations seeking funding and helps decide which projects get support.
Next: 2025-22677 — Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V COCONUT MONKEY
The Maritime Administration is checking if the foreign-built small passenger vessel M/V COCONUT MONKEY can be used for U.S. coastwise trade without hurting American boat builders or businesses. They’re asking for public comments by January 12, 2026, to help decide. If approved, this could open doors for new passenger services but won’t cost taxpayers anything right now.